Background: Hypertension is a major risk factor for cardiovascular disease, and data regarding the efficacy and tolerability of telmisartan compared with losartan on blood pressure (BP) control in patients with hypertension.
Methods: Pertinent studies were selected through extensive searches of PubMed (1966 to 29 December 2007), Embase (1980 to 29 December 2007), and the Cochrane library (29 December 2007). Randomized clinical trials comparing telmisartan with losartan in patients with hypertension were selected using predefined criteria. The main efficacy measures were reduction in diastolic and systolic BP (DBP and SBP), and therapeutic response of DBP and SBP. The pooled estimates were carried out using RevMan version 4.2 software.
Results: Eleven studies involving 1,832 patients were included in the analysis. Ten trials with 1,792 patients reported reduction in clinic BP; six trials with 1,163 patients reported ambulatory BP reduction; seven trials with 1,675 patients reported therapeutic response of BP. Funnel plots indicated that one trial had true heterogeneity. Use of telmisartan resulted in a significant reduction in clinic DBP (weighted mean difference 1.52, 95% confidence interval (CI) 0.85-2.19) and SBP (2.77, 1.90-3.63) when compared with losartan. There was also a significant reduction in 24-h mean ambulatory DBP (2.49, 0.56-4.42) and SBP (2.47, 0.40-4.55) with telmisartan as compared to losartan. There was also a significant increase in therapeutic response of DBP (relative risk (RR) 1.14, 1.04-1.23) and SBP response (1.10, 1.01-1.20) with telmisartan as compared to losartan. Both telmisartan and losartan were well tolerated.
Conclusions: In comparison with losartan, telmisartan provides superior control of BP and has no association with increased risk of adverse events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/ajh.2008.30 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sustainability assessment of the micellar optimized HPLC method for concomitant quantification of a common triple regimen for cardiovascular disorders: application to marketed formulations and dissolution testing.
Anal Methods
January 2025
Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
Hypertension and dyslipidemia are two of the most frequently co-occurring cardiovascular risk factors. The combined regimen of hydrochlorothiazide (HCTZ), rosuvastatin (ROS), and losartan (LOS) helped in the successful management of both conditions. This work's objective is to develop an eco-friendly, sensitive, simple, and reliable chromatographic method for the simultaneous estimation of HCTZ, ROS, and the LOS ternary mixture in their pure form, and pharmaceutical formulations.
View Article and Find Full Text PDFSaracatinib, a Src kinase inhibitor, enhances the renoprotective effect of metformin and losartan in diabetic nephropathy.
Arch Physiol Biochem
January 2025
Medical Physiology Department, Faculty of Medicine, Menoufia University, Shebin el Kom, Egypt.
Objective: This research assesses renoprotective effects of saracatinib (Src) in diabetic nephropathy (DN) and the potential underlying processes.
Materials And Methods: Rats were divided into: control, DN, DN + Met + Los, DN + Met + Src, and DN + Met + Los + Src. Rats' ABP, urinary albumin, urinary nephrin, and creatinine clearance were assessed.
L. Leaf Extract Dose-Dependently Modulates Oxidative Stress in the Kidney and Exerts Anti-Fibrotic and Anti-Inflammatory Properties by the Molecular Mechanisms Independent of NRF-2 Signalization Mirroring the Effects of Losartan in SHR.
Int J Mol Sci
December 2024
Department for Cardiovascular Physiology, Institute for Medical Research, National Institute of Republic of Serbia, University of Belgrade, Dr Subotića 4, P.O. Box 39, 11129 Belgrade, Serbia.
Previously, we confirmed systemic antihypertensive and antioxidant properties of L. leaf extract (UE) in spontaneously hypertensive rats (SHR). Here, we aimed to evaluate whether UE can alter the NO and Nrf-2 signaling to prevent local oxidative stress and kidney damage in the model of essential hypertension.
View Article and Find Full Text PDFComparison of the effect of Sacubitril/Valsartan with Losartan and Captopril in improving right ventricular function in patients with right heart failure, a randomized clinical controlled trial.
J Prev Med Hyg
September 2024
Department of Cardiology, School of Medicine, Health Management and Economics Research Center, Hazrat-e Rasool General Hospital, Iran University of Medical Sciences, Tehran, Iran.
Background: There is evidence supporting the efficacy of Sacubitril /Valsartan for improving left heart failure, but few studies have examined its effects on right ventricular (RV) dysfunction. The current study aimed to investigate the effects of Sacubitril /Valsartan on RV dysfunction in patients with right heart failure.
Methods: The current study was a randomized and parallel clinical trial study.
Integrating network pharmacology and experimental validation to explore the pharmacological mechanism of Astragaloside IV in alleviating urotensin II-mediated renal tubular epithelial cell injury.
PLoS One
December 2024
Department of Nephrology, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi, China.
Renal tubular epithelial cell injury is an important manifestation of chronic kidney disease (CKD). This study aims to explore the mechanism of astragaloside IV (AS-IV) in the treatment of UII-mediated renal tubular epithelial cell injury by integrating network pharmacology and experimental validation. BATMAN, SwissTarget-Prediction and ETCM data bases were used to screen the target proteins of AS-IV.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!